Sigyn Therapeutics (SIGY) Return on Capital Employed (2018 - 2025)
Sigyn Therapeutics (SIGY) posted Return on Capital Employed of 48.26% for Q3 2025, up 11.98% sequentially from 43.1% in Q2 2025, and down 2244.0% YoY from 2.25% in Q3 2024.
Sigyn Therapeutics (SIGY) Return on Capital Employed (2018 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Return on Capital Employed for 8 years, with the latest figure at 48.26% in Q3 2025.
- Quarterly Return on Capital Employed fell 2244.0% year-over-year to 48.26% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 48.26% (down 2244.0% YoY) and the FY2024 annual result came in at 57.95%, down 1689.0% from the prior year.
- Return on Capital Employed rose to 48.26% in Q3 2025 per SIGY's latest filing, from 43.1% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 2986.18% in Q1 2021 and troughed at 588.36% in Q4 2021.
- A 5-year average of 198.57% and a median of 70.7% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2021 and 2022: Return on Capital Employed surged 101300 bps in 2021, then tumbled 239067 bps in 2022.
- Over 5 years, Return on Capital Employed stood at 588.36% in 2021, then jumped by 121 bps to 126.23% in 2022, then sank by 40 bps to 75.47% in 2023, then slipped by 22 bps to 58.66% in 2024, then decreased by 18 bps to 48.26% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 48.26%, 43.1%, and 49.47% for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 48.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 48.26% |
| Jun 30, 2025 | 43.10% |
| Mar 31, 2025 | 49.47% |
| Dec 31, 2024 | 58.66% |
| Sep 30, 2024 | 70.70% |
| Jun 30, 2024 | 72.47% |
| Mar 31, 2024 | 65.54% |
| Dec 31, 2023 | 75.47% |
| Sep 30, 2023 | 64.12% |
| Jun 30, 2023 | 76.81% |
| Mar 31, 2023 | 88.12% |
| Dec 31, 2022 | 126.23% |
| Sep 30, 2022 | 148.74% |
| Jun 30, 2022 | 244.77% |
| Mar 31, 2022 | 595.51% |
| Dec 31, 2021 | -588.36% |
| Sep 30, 2021 | -198.65% |
| Jun 30, 2021 | -254.32% |
| Mar 31, 2021 | 2,986.18% |
| Dec 31, 2020 | -1,601.36% |